Evidence map›Paper›PMID 31550449›Full record

ArticleAntiviral research2019

Octadecyloxyethyl benzyl tenofovir: A novel tenofovir diester provides sustained intracellular levels of tenofovir diphosphate.

James R Beadle, Kathy A Aldern, Xing-Quan Zhang, Nadejda Valiaeva, Karl Y Hostetler, Robert T Schooley

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Tenofovir amibufenamideWorld journal of gastroenterology · 2023
    Article
  3. Article
  4. An Update on Antiretroviral Therapy.Advances in experimental medicine and biology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

James R BeadleDepartment of Medicine, Division of Infectious Disease and Global Public Health, University of California San Diego, La Jolla, CA, 92093, USA.
Kathy A AldernDepartment of Medicine, Division of Infectious Disease and Global Public Health, University of California San Diego, La Jolla, CA, 92093, USA.
Xing-Quan ZhangDepartment of Medicine, Division of Infectious Disease and Global Public Health, University of California San Diego, La Jolla, CA, 92093, USA.
Nadejda ValiaevaDepartment of Medicine, Division of Infectious Disease and Global Public Health, University of California San Diego, La Jolla, CA, 92093, USA.
Karl Y HostetlerDepartment of Medicine, Division of Infectious Disease and Global Public Health, University of California San Diego, La Jolla, CA, 92093, USA. Electronic address: khostetler@ucsd.edu.
Robert T SchooleyDepartment of Medicine, Division of Infectious Disease and Global Public Health, University of California San Diego, La Jolla, CA, 92093, USA.
University of California, San Diego · US

Funding

Development of Sustained-Release Anti-HIV Nucleoside Phosphonate NanoparticlesR01AI131424 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SCHOOLEY, ROBERT TURNER · 2017 to 2021
$3.8M
Optimization of HPMPA and CDV Analogs for Treatment of SmallpoxR01AI074057 · NIAID · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI HOSTETLER, KARL Y · 2008 to 2011
$2.2M
ANALOGS OF HPMPA FOR TREATMENT OF SMALLPOXR01AI066499 · NIAID · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI HOSTETLER, KARL Y · 2005 to 2005
$1.4M
POTENT NEW NUCLEOSIDE ANALOGS FOR DRUG RESISTANT HIVR01AI071803 · NIAID · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI HOSTETLER, KARL Y · 2007 to 2010
$1.3M
Nucleoside Phosphonate Analogs and HPV Positive CancersR01CA105039 · NCI · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI HOSTETLER, KARL Y · 2004 to 2007
$1.1M
PRODRUGS FOR THERAPY OF VIRAL RETINITIS IN AIDSR01EY011832 · NEI · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI HOSTETLER, KARL Y · 1997 to 2002
$1.1M
NCI NIH HHS R01 CA105039NEI NIH HHS R01 EY011832NIAID NIH HHS R01 AI066499NIAID NIH HHS R01 AI071803NIAID NIH HHS R01 AI074057NIAID NIH HHS R01 AI131424
6 · The paper itself

Abstract

Pre-exposure prophylaxis (PrEP) with topically or systemically administered antiretroviral agents can prevent acquisition of human immunodeficiency virus type 1 (HIV-1) infection. However, in clinical trials using tenofovir-containing agents, HIV-1 acquisition is reduced but not eliminated. Incomplete adherence remains the major contributor to failure. Sustained release or long-acting antiretroviral agents may provide better HIV-1 protection by reducing the clinical impact of incomplete adherence. To reduce dosing frequency, we synthesized a novel tenofovir prodrug, octadecyloxyethyl benzyl tenofovir (ODE-Bn-TFV), that is designed to release TFV slowly in tissues, and showed potent anti-HIV activity in vitro (EC

Indexed as

AdenineChemistry Techniques, SyntheticEstersHumansMolecular StructureOrganophosphatesTenofovirTissue DistributionAdenineEstersOrganophosphatesTenofovirtenofovir diphosphateAdherenceHIV-1 prophylaxisLong-acting antiretroviralTenofovir

Identifiers

PMID31550449
PMCPMC6927535
OpenAlexW2973732806

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.